Biotech

Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided a business update. As quoted in the press release: “2017 was a transformative year for Wave as we transitioned into …

Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided a business update.

As quoted in the press release:

“2017 was a transformative year for Wave as we transitioned into clinical development by initiating trials for our three lead neurology programs, established our in-house manufacturing capability and made great progress on delivering three more neurology development programs in 2018,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Our expertise in designing potentially first-in-class and innovative medicines continues to grow as we generate additional in vivo data demonstrating the impressive pharmacodynamic and pharmacokinetic properties of stereopure oligonucleotides in a variety of animal models across multiple organ systems and tissues. We look forward to advancing our existing and planned clinical programs, collaborating with our partners at Takeda and continuing to build our internal capabilities in preparation for the potential commercialization of our lead programs.”

Click here to read the full press release.

MARKETS

Markets
TSX18834.16-194.70
TSXV615.94-7.29
DOW30967.82-129.44
S&P 5003831.39+6.06
NASD11322.24+194.39
ASX6629.30+16.70

COMMODITIES

Commodities
Gold1761.23-7.63
Silver19.15-0.07
Copper3.39-0.02
Palladium1950.50+22.50
Platinum862.50-2.50
Oil99.91+0.41
Heating Oil3.58-0.02
Natural Gas5.57+0.05

DOWNLOAD FREE REPORTS

×